Go to content
UR Home

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3

URN to cite this document:
DOI to cite this document:
Wachholz, Vanessa ; Mustafa, Al-Hassan M. ; Zeyn, Yanira ; Henninger, Sven J. ; Beyer, Mandy ; Dzulko, Melanie ; Piée-Staffa, Andrea ; Brachetti, Christina ; Haehnel, Patricia S. ; Sellmer, Andreas ; Mahboobi, Siavosh ; Kindler, Thomas ; Brenner, Walburgis ; Nikolova, Teodora ; Krämer, Oliver H.
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 29 Feb 2024 12:41


Acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase (FLT3) is a clinically unresolved problem. AML cells frequently have a dysregulated expression and activity of epigenetic modulators of the histone deacetylase (HDAC) family. Therefore, we tested whether a combined inhibition of mutant FLT3 and class I HDACs is effective against AML cells. Low nanomolar doses of the FLT3 ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons